JUNS

← Markets

JUNSJupiter Neurosciences, Inc.

Discussion

Nothing said here yet.

to join the conversation.

—

Fri, Aug 21
1:01 PMSeeking AlphaJupiter Neurosciences announces pricing of $2M registered direct offering
11:20 AMstocktitan.netJupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
Wed, Aug 19
11:32 AMYahooReal Parkinson’s Disease Hope from Jupiter Neurosciences
Wed, Aug 5
7:00 AMYahooJupiter Neurosciences, Inc. Announces Reverse Stock Split
Wed, Jul 22
12:25 PMYahooPsychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva
Tue, Jul 21
9:27 AMinvestorshub.advfn.comJupiter Neurosciences Signs ALA-002 License Agreement Worth Up to $100 Million (NASDAQ:JUNS)
6:13 AMYahooJupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
6:00 AMYahooPharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
Tue, Jul 7
7:58 AMYahooJupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson
Tue, May 26
11:00 AMYahooD. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering
Wed, May 20
7:15 AMYahooPharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million
6:38 AMYahooJupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech